Patents Assigned to UAB Research Foundation
  • Patent number: 11421005
    Abstract: The invention provides chimeric antigen receptor(s) (CAR(s)) that comprise a fusion protein of CTX or any functional variant thereof or a CTX-like peptide or any functional variant thereof as the extracellular antigen recognition moiety of the CAR. CAR(s) comprising CTX, a CTX-like peptide or functional variants of the foregoing are collectively referred to herein as “CTX-CAR(s).” Such CTX-CAR(s) may further comprise additional moieties or domains in the extracellular domain, a transmembrane domain and at least one intracellular! signaling domain. Such CTX-CAR(s) may be expressed in a host cell, such as, but not limited to, an immune effector cell. The present invention also provides methods of treatment (such as, for example, methods for treating cancer) by providing to the patient in need thereof immune effector cells that are engineered to express a CTX-CAR described herein.
    Type: Grant
    Filed: December 9, 2017
    Date of Patent: August 23, 2022
    Assignee: The UAB Research Foundation
    Inventors: Lawrence S. Lamb, Jr., Antonio Di Stasi, G. Yancey Gillespie, Larisa Pereboeva
  • Publication number: 20220169683
    Abstract: Provided herein are mutant single-chain Mycobacterium smegmatis porin (Msp) and uses thereof.
    Type: Application
    Filed: February 17, 2022
    Publication date: June 2, 2022
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventors: Michael Niederweis, Mikhail Pavlenok
  • Patent number: 11332502
    Abstract: Adeno associated viral (AAV) particles are emerging as a useful vehicle for gene delivery to various organs and tissues, one of them being the retina. Provided here are variant AAV (e.g., variant serotype 2 (AAV2)) capsid proteins and variant capsid protein containing particles with enhanced ability to transduce retinal cells.
    Type: Grant
    Filed: September 1, 2020
    Date of Patent: May 17, 2022
    Assignees: University of Florida Research Foundation, Incorporated, The UAB Research Foundation
    Inventors: Sergei Zolotukhin, Sanford L. Boye, Shannon E. Boye, Damien Marsic, Nicholas Muzyczka, Hector Ruben Mendez-Gomez, Paul D. Gamlin
  • Publication number: 20220119511
    Abstract: Disclosed are novel treatments for diseases and conditions caused by, directly or indirectly, high blood glucose levels increased gluconeogenesis. Such disease and conditions include, but are not limited to, type II diabetes, obesity, and cardiovascular conditions. Sam68, an RNA-binding adaptor protein and Src kinase substrate, is a novel regulator of hepatic gluconeogenesis and global and hepatic deletions of Sam68 significantly reduce blood glucose levels and the glucagon-induced expression of gluconeogenic genes. The treatments described herein may include inhibition of the activity of Sam68.
    Type: Application
    Filed: October 15, 2021
    Publication date: April 21, 2022
    Applicant: The UAB Research Foundation
    Inventors: Gangjian QIN, Aijun QIAO
  • Patent number: 11298014
    Abstract: The present disclosure provides an improved method for photobleaching an eye of a subject. The disclosed method may be used in a number of psychophysical test methods, including, but not limited to, measurement of dark adaptation. The improved method for photobleaching involves at least one of the following improvements: (i) the use of a bleaching light emitting a particular wavelength of light or a tailored spectrum of wavelengths; (ii) restricting or otherwise spatially tailoring the region of the retina that is subject to photobleaching; and (iii) utilizing a bleaching light having an intensity that is at or below the intensity of ambient daylight. The present disclosure additionally provides a combination of a photobleaching light and an apparatus to administer a psychophysical test suitable for use in practicing the disclosed methods.
    Type: Grant
    Filed: November 9, 2021
    Date of Patent: April 12, 2022
    Assignee: The UAB Research Foundation
    Inventors: John G. Edwards, Gregory R. Jackson
  • Patent number: 11292817
    Abstract: Provided herein are mutant single-chain Mycobacterium smegmatis porin (Msp) and uses thereof.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: April 5, 2022
    Assignee: THE UAB RESEARCH FOUNDATION
    Inventors: Michael Niederweis, Mikhail Pavlenok
  • Patent number: 11295445
    Abstract: A method for ascertaining pulmonary fibrosis disease progression or treatment response includes obtaining a first set of computed tomography (CT) images of a lung and determining a first Pulmonary Surface Index (PSI) score for the lung by detecting a first actual lung boundary of the lung within the first set of CT images, determining a first approximated lung boundary within the first set of CT images, and determining the PSI score using inputs based on the first actual lung boundary and the first approximated lung boundary. The method also includes obtaining a second set of CT images of the lung and determining a second PSI score for the lung using inputs based on a second actual lung boundary and a second approximated lung boundary. The method also includes assessing pulmonary fibrosis treatment response or disease progression based on the first PSI score and the second PSI score.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: April 5, 2022
    Assignee: THE UAB RESEARCH FOUNDATION
    Inventor: Andrew Dennis Smith
  • Publication number: 20220088145
    Abstract: Provided herein are methods and compositions for treating and preventing inflammatory bowel disease.
    Type: Application
    Filed: February 7, 2020
    Publication date: March 24, 2022
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventors: Charles O. Elson, Wayne Duck, Qing Zhao, Katie Alexander
  • Publication number: 20220053324
    Abstract: The present disclosure relates exposure notification, and in particular to techniques for verification of positive test results from public health authorities where individuals submit notice using public health approved mobile applications for exposure notification and/or contact tracing. When an individual attempts to submit a positive test result notification in a mobile application, the associated device's mobile number will be requested. This mobile number will then be sent a verification code to be entered in the application. At this point, these codes shall be stored digitally in escrow. A regular data feed from a health authority shall be provided that shall include an agreed encryption (irreversibly encrypted or reversibly encrypted) of the mobile numbers associated with any reported test. Any results submitted in the application that have a matching encryption of the mobile numbers shall be released from the escrow for subsequent notification.
    Type: Application
    Filed: August 16, 2021
    Publication date: February 17, 2022
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventors: Claude B. Rivers, Rajesh B. Pillai, Zekai Demirezen, Jaret A. Langston
  • Patent number: 11247971
    Abstract: Provided is a compound of formula (I), in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: February 15, 2022
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE UAB RESEARCH FOUNDATION, VANDERBILT UNIVERSITY, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: David J. Maloney, Alex Gregory Waterson, Ganesh Rai Bantukallu, Kyle Ryan Brimacombe, Plamen Christov, Chi V. Dang, Victor Darley-Usmar, Xin Hu, Ajit Jadhav, Somnath Jana, Kwangho Kim, Jennifer L. Kouznetsova, William J. Moore, Bryan T. Mott, Leonard M. Neckers, Anton Simeonov, Gary Allen Sulikowski, Daniel Jason Urban, Shyh Ming Yang
  • Publication number: 20220031817
    Abstract: The use of a purine nucleoside phosphorylase or nucleoside hydrolase or a vector encoding expression of one of these enzymes is detailed along with the use of a prodrug cleaved by the purine nucleoside phosphorylase or nucleoside hydrolase for the preparation of a direct injection inhibition of replicating or non-replicating targeted cells. The targeted cells do not normally express the introduced purine nucleoside phosphorylase or nucleoside hydrolase. The enzyme and prodrug are amenable to intermixing and injection as a single dose or as separate injection or administration to the targeted cells. The substance and prodrug efficacy are enhanced through exposure of the targeted cells to X-ray radiation. Administration of a prodrug regardless of administration route to the targeted cells is effective in combination with X-ray radiation therapy to kill or inhibit function of the targeted cells.
    Type: Application
    Filed: October 15, 2021
    Publication date: February 3, 2022
    Applicants: The UAB Research Foundation, Southern Research Institute
    Inventors: William B. Parker, Eric J. Sorscher
  • Patent number: 11224340
    Abstract: The present disclosure provides an improved method for photobleaching an eye of a subject. The disclosed method may be used in a number of psychophysical test methods, including, but not limited to, measurement of dark adaptation. The improved method for photobleaching involves at least one of the following improvements: (i) the use of a bleaching light emitting a particular wavelength of light or a tailored spectrum of wavelengths; (ii) restricting or otherwise spatially tailoring the region of the retina that is subject to photobleaching; and (iii) utilizing a bleaching light having an intensity that is at or below the intensity of ambient daylight. The present disclosure additionally provides a combination of a photobleaching light and an apparatus to administer a psychophysical test suitable for use in practicing the disclosed methods.
    Type: Grant
    Filed: June 16, 2021
    Date of Patent: January 18, 2022
    Assignee: The UAB Research Foundation
    Inventors: John G. Edwards, Gregory R. Jackson
  • Patent number: 11213507
    Abstract: Provided is a darwinolide compound having a previously undescribed carbon skeleton and the crystalline form thereof. Also provided are processes of isolating darwinolide, compositions comprising darwinolide, and methods of treating infection, such as a methicillin-resistant Staphylococcus aureus biofilm infection.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: January 4, 2022
    Assignees: UNIVERSITY OF SOUTH FLORIDA, UAB RESEARCH FOUNDATION
    Inventors: Bill J. Baker, Lindsey N. Shaw, James Bruce McClintock, Charles D. Amsler, Jacqueline Lee Fries, Witowski G. Christopher, Renee M. Fleeman
  • Publication number: 20210405025
    Abstract: Provided herein is a method for identifying compounds that inhibit cell growth or have cytotoxic activity against cancer cells, such as hematological cancer cells or ovarian cancer cells, in a subject. Further provided is a method for identifying one or more compounds that sensitize refractory cancer cells from a subject. Also provided are compositions and methods for treating cancer, including refractory cancer, such as refractory acute myeloid leukemia (AML) or ovarian cancer.
    Type: Application
    Filed: June 14, 2019
    Publication date: December 30, 2021
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventor: Christopher Klug
  • Publication number: 20210369713
    Abstract: In one aspect, compounds and compositions that inhibit TXNIP expression and/or that lower hepatic glucose production and methods of identifying, making, and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with elevated TXNIP and/or elevated glucagon levels such as, for example, diabetes and associated disorders. Further provided are methods for treating hyperlipidemia or fatty liver disease, optionally associated with elevated TXNIP and/or elevated glucagon levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: July 13, 2021
    Publication date: December 2, 2021
    Applicants: SOUTHERN RESEARCH INSTITUTE, THE UAB RESEARCH FOUNDATION
    Inventors: Corinne E. Augelli-Szafran, Omar Moukha-Chafiq, Mark J. Suto, Anath Shalev, Lance Thielen, Junqin Chen, Gu Jing
  • Publication number: 20210323933
    Abstract: The present disclosure is concerned with piperazine-2,5-diones that are capable of inhibiting TGF-? and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: August 5, 2019
    Publication date: October 21, 2021
    Applicant: UAB Research Foundation
    Inventors: Mark J. Suto, Vandana V. Gupta, Wei Zhang, Joanne Murphy-Ullrich
  • Patent number: 11141443
    Abstract: The respiratory microbiomes of neonates and those with bronchopulmonary disease have been characterized. Provided are probiotic compositions, which can include at least one living bacterial strain and at least one killed bacterial strain, that can comprise a combination of Lactobacilli species, 5 that when delivered to the bronchi or lungs of a patient can provide a reduction in the symptoms of a bronchopulmonary disease.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: October 12, 2021
    Assignee: THE UAB RESEARCH FOUNDATION
    Inventors: Charitharth Vivek Lal, Namasivayam Ambalavanan, Amit Gaggar, Casey Morrow
  • Patent number: 11103508
    Abstract: In one aspect, compounds and compositions that inhibit TXNIP expression and/or that lower hepatic glucose production and methods of identifying, making, and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with elevated TXNIP and/or elevated glucagon levels such as, for example, diabetes and associated disorders. Further provided are methods for treating hyperlipidemia or fatty liver disease, optionally associated with elevated TXNIP and/or elevated glucagon levels.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: August 31, 2021
    Assignees: SOUTHERN RESEARCH INSTITUTE, THE UAB RESEARCH FOUNDATION
    Inventors: Corinne E. Augelli-Szafran, Omar Moukha-Chafiq, Mark J. Suto, Anath Shalev, Lance Thielen, Junqin Chen, Gu Jing
  • Patent number: 11096932
    Abstract: Provided herein are methods of increasing mucus clearance in a subject having decreased mucus clearance. Also provided are methods of treating or preventing a respiratory disorder.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: August 24, 2021
    Assignee: THE UAB RESEARCH FOUNDATION
    Inventors: Sammeta Vamsee Raju, Lawrence Rasmussen, Steven Mark Rowe
  • Publication number: 20210253676
    Abstract: Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed.
    Type: Application
    Filed: December 18, 2020
    Publication date: August 19, 2021
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventors: Max D. Cooper, Brantley R. Herrin, Matthew N. Alder